Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Matthay

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic MarkersFarzad Moazed, Carolyn Hendrickson, Alejandra Jauregui, et al.
Plos One|February 2, 2012
Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major traumaJason D Christie, Mark M Wurfel, Rui Feng, et al.
ESC Heart Failure|June 10, 2021
Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of deathKamilė Čerlinskaitė, Alexandre Mebazaa, Raphaël Cinotti, et al.
Cytotherapy|November 24, 2024
Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeuticsLaurent Renesme, Kelly D Cobey, Manoj M Lalu, et al.
Biorxiv : the Preprint Server for Biology|June 8, 2021
SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediatorLisiena Hysenaj, Samantha Little, Kayla Kulhanek, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Elife|November 19, 2025
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
The Lancet. Respiratory Medicine|March 19, 2026
Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trialErik H A Michels, Pierre-François Dequin, Joe M Butler, et al.
Medrxiv : the Preprint Server for Health Sciences|January 25, 2022
Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without VaccinationRahul K Suryawanshi, Irene P Chen, Tongcui Ma, et al.
Research Square|November 3, 2020
Global Absence and Targeting of Protective Immune States in Severe COVID-19Alexis J Combes, Tristan Courau, Nicholas F Kuhn, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic MarkersFarzad Moazed, Carolyn Hendrickson, Alejandra Jauregui, et al.
Plos One|February 2, 2012
Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major traumaJason D Christie, Mark M Wurfel, Rui Feng, et al.
ESC Heart Failure|June 10, 2021
Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of deathKamilė Čerlinskaitė, Alexandre Mebazaa, Raphaël Cinotti, et al.
Cytotherapy|November 24, 2024
Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeuticsLaurent Renesme, Kelly D Cobey, Manoj M Lalu, et al.
Biorxiv : the Preprint Server for Biology|June 8, 2021
SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediatorLisiena Hysenaj, Samantha Little, Kayla Kulhanek, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Elife|November 19, 2025
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
The Lancet. Respiratory Medicine|March 19, 2026
Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trialErik H A Michels, Pierre-François Dequin, Joe M Butler, et al.
Medrxiv : the Preprint Server for Health Sciences|January 25, 2022
Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without VaccinationRahul K Suryawanshi, Irene P Chen, Tongcui Ma, et al.
Research Square|November 3, 2020
Global Absence and Targeting of Protective Immune States in Severe COVID-19Alexis J Combes, Tristan Courau, Nicholas F Kuhn, et al.
Pageof 5